title: The role of bevacizumab in hearing preservation and tumor volume control in patients with vestibular schwannomas.
authors.forename: Ricardo J
authors.initials: RJ
authors.lastname: Komotar
authors.forename: Robert M
authors.initials: RM
authors.lastname: Starke
authors.forename: Michael B
authors.initials: MB
authors.lastname: Sisti
authors.forename: E Sander
authors.initials: ES
authors.lastname: Connolly
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D034381:Hearing Loss / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D009464:Neuroma, Acoustic / Q000150:complications* / Q000473:pathology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab